Takeuchi Kumiko, Kohn Todd J, Honigschmidt Nicholas A, Rocco Vincent P, Spinazze Patrick G, Koch Daniel J, Atkinson Steven T, Hertel Larry W, Nelson David L, Wainscott D Bradley, Ahmad Laura J, Shaw Janice, Threlkeld Penny G, Wong David T
Lilly Research Laboratories, A Division of Eli Lilly and Company, IN 46285, Indianapolis, USA.
Bioorg Med Chem Lett. 2003 Jul 21;13(14):2393-7. doi: 10.1016/s0960-894x(03)00392-5.
Potent 5-HT1A/SSRIs at low nanomolar and subnanomolar concentrations were identified in a series of 1-(1H-indol-4-yloxy)-3-(4-benzo[b]thiophen-2-ylpiperidinyl)propan-2-ols. Incorporation of an alpha-Me group in the piperidine ring with its specific stereochemistry enhanced binding affinity at the 5-HT reuptake site and in vitro 5-HT(1A) antagonist functional activity.